Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Aclaris Therapeutics to Host In-Person and Webcast R&D Day in New York on October 14, 2025
-
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation at the 2025 European Academy of Dermatology and Ve
-
Aclaris Therapeutics to Participate in Two September Healthcare Conferences
-
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of IT
-
Aclaris Therapeutics Announces Scientific Leadership Transition
-
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
-
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
-
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
-
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis